TWI760999B - Use of atemoya extract for whitening skin, improving skin elasticity, and protecting skin from uv damage - Google Patents
Use of atemoya extract for whitening skin, improving skin elasticity, and protecting skin from uv damage Download PDFInfo
- Publication number
- TWI760999B TWI760999B TW109146335A TW109146335A TWI760999B TW I760999 B TWI760999 B TW I760999B TW 109146335 A TW109146335 A TW 109146335A TW 109146335 A TW109146335 A TW 109146335A TW I760999 B TWI760999 B TW I760999B
- Authority
- TW
- Taiwan
- Prior art keywords
- pineapple
- extract
- skin
- gene
- cells
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 116
- 230000037394 skin elasticity Effects 0.000 title claims abstract description 13
- 230000002087 whitening effect Effects 0.000 title abstract description 11
- 230000006378 damage Effects 0.000 title abstract description 5
- 235000010870 Annona cherimola x Annona squamosa Nutrition 0.000 title abstract 4
- 235000017401 Annona x atemoya Nutrition 0.000 title abstract 4
- 244000137984 Annona x atemoya Species 0.000 title abstract 4
- 235000007119 Ananas comosus Nutrition 0.000 claims description 141
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 58
- 210000003491 skin Anatomy 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000003425 Tyrosinase Human genes 0.000 claims description 24
- 108060008724 Tyrosinase Proteins 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 22
- 230000002438 mitochondrial effect Effects 0.000 claims description 15
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 210000004927 skin cell Anatomy 0.000 claims description 12
- 239000003610 charcoal Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 101150063226 parp-1 gene Proteins 0.000 claims description 10
- 101150003919 Parp2 gene Proteins 0.000 claims description 8
- 101150117904 Nadsyn gene Proteins 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 5
- 244000021317 Annona cherimola Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229940030961 sorghum extract Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 235000002272 Annona cherimola Nutrition 0.000 claims description 3
- 244000028821 Annona squamosa Species 0.000 claims description 3
- 235000005274 Annona squamosa Nutrition 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims 7
- 240000002022 Anthriscus cerefolium Species 0.000 claims 2
- 235000007258 Anthriscus cerefolium Nutrition 0.000 claims 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims 1
- 235000013824 polyphenols Nutrition 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 abstract 1
- 241000234671 Ananas Species 0.000 description 134
- 210000004027 cell Anatomy 0.000 description 86
- 239000000243 solution Substances 0.000 description 59
- 238000000034 method Methods 0.000 description 43
- 238000002474 experimental method Methods 0.000 description 36
- 239000002609 medium Substances 0.000 description 34
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 28
- 239000002953 phosphate buffered saline Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 235000011950 custard Nutrition 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 24
- 238000010438 heat treatment Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000002994 raw material Substances 0.000 description 19
- 102000016942 Elastin Human genes 0.000 description 14
- 108010014258 Elastin Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 229920002549 elastin Polymers 0.000 description 14
- 230000008099 melanin synthesis Effects 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 12
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 9
- 239000003125 aqueous solvent Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 210000001626 skin fibroblast Anatomy 0.000 description 8
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 7
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 7
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 7
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 7
- 229960004705 kojic acid Drugs 0.000 description 7
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 235000021538 Chard Nutrition 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229940119217 chamomile extract Drugs 0.000 description 6
- 235000020221 chamomile extract Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000007758 minimum essential medium Substances 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 229940054269 sodium pyruvate Drugs 0.000 description 6
- 101100025586 Drosophila melanogaster Nadsyn gene Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000012154 double-distilled water Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 3
- 102100022624 Glucoamylase Human genes 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000036564 melanin content Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000012984 antibiotic solution Substances 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- -1 troche Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150106024 Aqp3 gene Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101150063233 FLG gene Proteins 0.000 description 1
- 101150028412 GBA gene Proteins 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101150089672 HAS3 gene Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101150027313 Has2 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 108010028688 Isoamylase Proteins 0.000 description 1
- 101150040052 KRT14 gene Proteins 0.000 description 1
- 101150056422 Krt1 gene Proteins 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940013712 pineapple extract Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011110 re-filtration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 101150023847 tbp gene Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 101150022728 tyr gene Proteins 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/06—Products with modified nutritive value, e.g. with modified starch content
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本案係關於一種鳳梨釋迦萃取物的用途,特別是關於一用於製備肌膚美白、抵禦紫外線損傷及提升肌膚彈性之組合物的用途。This case is about the use of an extract of pineapple chard, especially the use of a composition for preparing skin whitening, anti-ultraviolet damage and improving skin elasticity.
鳳梨釋迦(Annona cherimola ×Annona squamosa )又稱為蜜釋迦、旺來釋迦、奇美釋迦,是冷子番荔枝(Annona cherimola )與番荔枝(Annona squamosa )之雜交種,最早係於1908年在美國佛羅里達洲所育成。鳳梨釋迦為多年生小喬木,莖高 3~10 公尺;葉屬單葉互生,葉柄長約 1.5~2 公分,葉緣平滑;花瓣 3 枚,呈3稜角長形,淡綠色下垂。鳳梨釋迦之果肉係相連,與釋迦(番荔枝)瓣狀之果肉不同。一般而言,鳳梨釋迦果實可達600公克以上。Pineapple Sakya ( Annona cherimola × Annona squamosa ), also known as Honey Sakya, Wanglai Sakya and Chimei Sakya, is a hybrid of Annona cherimola and Annona squamosa . It was first introduced in Florida in 1908. Continent bred. Pineapple Sakyamuni is a small perennial tree with a stem height of 3 to 10 meters; leaves are single alternate leaves, petioles about 1.5 to 2 cm long, with smooth leaf margins; 3 petals, 3 angular and long, pale green drooping. The pulp of pineapple sakya is connected, which is different from the petal-shaped pulp of sakya (sweet apple). Generally speaking, pineapple sakya fruit can reach more than 600 grams.
皮膚對於人類個體之保護具有不可或缺之重要性,其提供了對抗陽光中紫外線輻射、病原體、摩擦力等環境因子的第一階段保護。通常,年輕的肌膚具有較佳的支撐性以及彈性,然隨年齡增長或環境因子,皮膚會逐漸老化。舉例而言,皮膚可能會因為膠原蛋白裂解,導致肌膚彈力下降或因黑色素沉澱,使肌膚整體較為暗沈等老化狀態。The skin is of indispensable importance for the protection of the human individual, providing the first stage of protection against environmental factors such as UV radiation in the sun, pathogens, friction, etc. Generally, young skin has better support and elasticity, but with age or environmental factors, the skin will gradually age. For example, the skin may be degraded due to collagen breakdown, resulting in decreased skin elasticity or due to the precipitation of melanin, making the overall skin dull and other aging states.
有鑑於此,研究或開發一種可提升肌膚白皙度與彈性之組合物,來維持或改善肌膚外觀乃有其必要。In view of this, it is necessary to research or develop a composition that can improve skin fairness and elasticity to maintain or improve skin appearance.
緣此,本發明的一目的在於提供一種鳳梨釋迦萃取物用於製備肌膚美白、提升肌膚彈性、及抵禦紫外線損傷之組合物的用途。Therefore, an object of the present invention is to provide the use of a pineapple sacha extract for preparing a composition for skin whitening, skin elasticity improvement, and ultraviolet damage protection.
具體而言,本發明的一目的在於提供一種鳳梨釋迦萃取物用於製備抑制肌膚細胞內酪胺酸酶活性、降低肌膚細胞內黑色素生成、提升肌膚細胞抵抗紫外線損傷、及提升肌膚彈性之組合物的用途。Specifically, an object of the present invention is to provide a pineapple sacha extract for preparing a composition for inhibiting tyrosinase activity in skin cells, reducing melanin production in skin cells, improving skin cells' resistance to ultraviolet damage, and improving skin elasticity the use of.
在一些實施例中,該組合物係為醫藥組合物。In some embodiments, the composition is a pharmaceutical composition.
在一些實施例中,該組合物係進一步製備成保養品組合物、保健食品組合物、或化妝品組合物。In some embodiments, the composition is further prepared into a skincare composition, a health food composition, or a cosmetic composition.
在一些實施例中,該鳳梨釋迦萃取物係以一含水之溶劑萃取一鳳梨釋迦果實所獲得。在一些實施例中,該含水之溶劑為純水。在一些實施例中,該含水之溶劑另包含一糖解酵素。在一些實施例中,該糖解酵素之濃度為0.1wt%。In some embodiments, the pineapple custard extract is obtained by extracting a pineapple custard fruit with an aqueous solvent. In some embodiments, the aqueous solvent is pure water. In some embodiments, the aqueous solvent further comprises a glycolytic enzyme. In some embodiments, the concentration of the glycolytic enzyme is 0.1 wt%.
在一些實施例中,鳳梨釋迦萃取物是以含水之溶劑形成初萃液,初萃液經糖化酵素酵解而形成鳳梨釋迦萃取物。In some embodiments, the pineapple chardonnay extract is formed by a water-containing solvent to form a primary extract, and the primary extract is lysed by saccharifying enzymes to form the pineapple chardonnay extract.
在一些實施例中,該鳳梨釋迦萃取物係透過抑制酪胺酸酶活性以提升肌膚之白皙度。In some embodiments, the pineapple charcoal extract improves skin fairness by inhibiting tyrosinase activity.
在一些實施例中,該鳳梨釋迦萃取物係透過減少肌膚細胞內黑色素生成以提升肌膚之白皙度。在一些實施例中,該黑色素生成係由紫外線所造成。In some embodiments, the pineapple charcoal extract improves skin fairness by reducing melanin production in skin cells. In some embodiments, the melanin production is caused by ultraviolet light.
在一些實施例中,該鳳梨釋迦萃取物係透過提升肌膚細胞內粒線體活性相關基因之表現量以達到提升細胞抵禦紫外線之能力。In some embodiments, the Pineapple Shakya extract enhances the ability of cells to resist ultraviolet rays by increasing the expression of mitochondrial activity-related genes in skin cells.
在一些實施例中,該粒線體活性相關基因為PARP1基因(Gene ID: 142)、PARP2(Gene ID: 10038)及NADSYN(Gene ID: 55191)。In some embodiments, the mitochondrial activity-related genes are PARP1 gene (Gene ID: 142), PARP2 (Gene ID: 10038) and NADSYN (Gene ID: 55191).
在一些實施例中,該鳳梨釋迦萃取物係透過肌膚細胞之彈力蛋白分泌以達到提升肌膚彈力。In some embodiments, the Pineapple Shakya extract enhances skin elasticity through the secretion of elastin from skin cells.
在一些實施例中,該鳳梨釋迦萃取物之濃度至少為0.25mg/mL。In some embodiments, the concentration of the pineapple custard extract is at least 0.25 mg/mL.
在一些實施例中,該鳳梨釋迦萃取物的白利糖度(Degrees Brix)值為8±0.5。In some embodiments, the pineapple custard extract has a Degrees Brix value of 8±0.5.
綜上所述,任一實施例的鳳梨釋迦萃取物可用於製備肌膚美白之組合物。任一實施例的鳳梨釋迦萃取物可用於製備抑制酪胺酸酶活性之組合物。任一實施例的鳳梨釋迦萃取物可用於製備抑制黑色素生成之組合物。任一實施例的鳳梨釋迦萃取物可用於製備提升肌膚細胞抵禦紫外線之能力之組合物。任一實施例的鳳梨釋迦萃取物可用於製備提升肌膚細胞內粒線體活性相關基因之表現量之組合物。任一實施例的鳳梨釋迦萃取物可用於製備提升肌膚細胞內彈力蛋白之分泌量之組合物。To sum up, the pineapple sacha extract of any embodiment can be used to prepare a skin whitening composition. The pineapple charcoal extract of any one of the embodiments can be used to prepare a composition for inhibiting tyrosinase activity. The pineapple charcoal extract of any one of the embodiments can be used to prepare a composition for inhibiting melanin production. The pineapple chard extract of any one of the embodiments can be used to prepare a composition for enhancing the ability of skin cells to resist ultraviolet rays. The pineapple sacha extract of any one of the embodiments can be used to prepare a composition for enhancing the expression of genes related to mitochondrial activity in skin cells. The pineapple sacha extract of any one of the embodiments can be used to prepare a composition for increasing the secretion of elastin in skin cells.
以下將描述本案的部分具體實施態樣。在不背離本案精神下,本案尚可以多種不同形式之態樣來實踐,不應將保護範圍限於說明書所具體陳述的條件。Some specific implementation aspects of this case will be described below. Without departing from the spirit of this case, this case can still be practiced in many different forms, and the scope of protection should not be limited to the conditions specifically stated in the description.
本案使用Excel軟體進行統計分析。數據以平均值±標準差(SD)表示,各組之間的差異以學生t檢驗(student’s t-test)進行分析。圖式中「*」代表p值小於0.05,「**」代表p值小於0.01,以及「***」代表p值小於0.001。當「*」越多時,代表統計上的差異越顯著。The case used Excel software for statistical analysis. Data are presented as mean ± standard deviation (SD), and differences between groups were analyzed by Student's t-test. In the graph, "*" represents a p-value less than 0.05, "**" represents a p-value less than 0.01, and "***" represents a p-value less than 0.001. The more "*", the more significant the statistical difference.
本文中所使用數值為近似值,所有實驗數據皆表示在正負10%的範圍內,最佳為在正負5%的範圍內。The numerical values used herein are approximate, all experimental data are expressed within the range of plus or minus 10%, and the optimum is within the range of plus or minus 5%.
本文中之「wt%」係指重量百分比,而「vol%」係指體積百分比。Herein, "wt%" refers to weight percent, and "vol%" refers to volume percent.
如本文中所使用,術語「萃取物」係指藉由萃取作用所製備之產物。該萃取物可以溶於溶劑中之溶液形式呈現,或萃取物可為不含或大體上不含溶劑之濃縮物或精華呈現。As used herein, the term "extract" refers to a product prepared by extraction. The extract may be presented as a solution in a solvent, or the extract may be presented as a concentrate or essence free or substantially free of solvent.
如本文所用「鳳梨釋迦原料」通常係指植物果實,其中果實可為含皮或不含皮之果實、經乾燥或以其他物理方式加工以利於處理之果實,其可進一步包含完整、剁碎、切丁、碾磨、研磨或以其他方式經加工以影響原物料之大小及實體完整性之果實。As used herein, "Pineapple Shakya raw material" generally refers to the fruit of the plant, wherein the fruit may be peeled or unskinned, dried or otherwise physically processed to facilitate handling, which may further include whole, chopped, Fruit that has been diced, milled, ground or otherwise processed to affect the size and physical integrity of the raw material.
參考圖1。在一些實施例中,一種鳳梨釋迦萃取物,其是由一種含水之溶劑對鳳梨釋迦原料進行萃取。在一些實施例中,鳳梨釋迦萃取物係將鳳梨釋迦原料依序進行粉碎程序S01、加熱程序S02、過濾程序S04、及濃縮程序S05後得到。Refer to Figure 1. In some embodiments, a pineapple custard extract is obtained by extracting pineapple custard raw material with an aqueous solvent. In some embodiments, the pineapple custard extract is obtained by sequentially performing the crushing process S01 , the heating process S02 , the filtering process S04 , and the concentration process S05 on the pineapple custard raw material.
在一些實施例中,鳳梨釋迦原料可以是含皮或不含皮的鳳梨釋迦果實。在一些實施例中,鳳梨釋迦原料可以是新鮮或乾燥的鳳梨釋迦果實。In some embodiments, the raw pineapple chard may be pineapple chard fruit with or without skin. In some embodiments, the raw material of pineapple can be fresh or dried pineapple fruit.
在一些實施例中,粉碎程序S01是指將鳳梨釋迦原料攪打至分裂為碎狀。舉例而言,粉碎可以採用果汁機、調理機或均質機。In some embodiments, the pulverizing procedure S01 refers to whipping the raw material of pineapple chakra until it is broken into pieces. For example, comminution can be performed using a juicer, conditioner or homogenizer.
在一些實施例中,加熱程序S02是指將碎狀的鳳梨釋迦原料與含水之溶劑混合後加熱一段固定時間。在一些實施例中,加熱是指將鳳梨釋迦原料與含水之溶劑的溫度提升到50℃~100℃。在一些實施例中,一段固定時間是指0.5小時到3小時。舉例而言,將鳳梨釋迦原料與含水之溶劑的溫度提升到85℃進行提取1小時。In some embodiments, the heating procedure S02 refers to mixing the crushed pineapple custard raw material with a water-containing solvent and heating for a fixed period of time. In some embodiments, heating refers to raising the temperature of the pineapple custard raw material and the water-containing solvent to 50°C to 100°C. In some embodiments, a fixed period of time refers to 0.5 hours to 3 hours. For example, the temperature of the pineapple custard raw material and the water-containing solvent is raised to 85° C. for extraction for 1 hour.
在一些實施例中,加熱程序S02中的重量比例(含水之溶劑:鳳梨釋迦原料)為5:1~20:1。舉例而言,含水之溶劑:鳳梨釋迦原料為10:1。In some embodiments, the weight ratio in the heating procedure S02 (a solvent containing water: a raw material of pineapple sago) is 5:1 to 20:1. For example, the solvent containing water: pineapple custard raw material is 10:1.
舉例而言,採用90公斤重的鳳梨釋迦原料、900公斤重的水及0.63公斤重的檸檬酸混合後持續加熱到100℃,並維持100℃持續0.5小時。舉例而言,採用90公斤重的鳳梨釋迦原料、900公斤重的水及0.7公斤重的檸檬酸混合後持續加熱到85℃,並維持85℃持續1小時。For example, 90 kg of pineapple custard raw material, 900 kg of water and 0.63 kg of citric acid are used to mix and continue to heat to 100°C, and maintain the temperature at 100°C for 0.5 hours. For example, 90 kg of pineapple custard raw material, 900 kg of water and 0.7 kg of citric acid are used to mix and continue to heat to 85°C and maintain at 85°C for 1 hour.
在一些實施例中,含水之溶劑可以是純水或含有有機酸之水溶劑。在一些實施例中,有機酸之濃度為0.05%到1.00%。在一些實施例中,有機酸可是可食用酸。在一些實施例中,可食用酸可以是檸檬酸(Citric Acid)、蘋果酸、酒石酸、乳酸、葡萄糖酸、醋酸等,並不以此為限。In some embodiments, the aqueous solvent may be pure water or an organic acid-containing aqueous solvent. In some embodiments, the concentration of organic acid is 0.05% to 1.00%. In some embodiments, the organic acid may be an edible acid. In some embodiments, the edible acid may be citric acid, malic acid, tartaric acid, lactic acid, gluconic acid, acetic acid, etc., but is not limited thereto.
在一些實施例中,含水之溶劑可另包含澱粉糖化酵素(Amylase)。在一些實施例中,加熱程序S02中是指將鳳梨釋迦原料與水及澱粉糖化酵素攪拌充分混合後,將其提升到50℃~100℃,持續一段時間。其中,藉由酵素的酵解作用可進一步提升鳳梨釋迦萃取物內有效成分的含量。在一些實施例中,澱粉糖化酵素可以是α-澱粉酶、β-澱粉酶、葡萄糖澱粉酶、異澱粉酶至少一或其混合。在一些實施例中,澱粉糖化酵素可以是葡萄糖澱粉酶(glucan 1,4-alpha-glucosidase)。在一些實施例中,澱粉糖化酵素的添加量為含水之溶劑的0.05%至0.15%,在一些實施例中,該含水之溶劑可為水。在一些實施例中,加熱程序S02是將鳳梨釋迦原料與水1:5混合後,添加0.1 %澱粉糖化酵素並加熱到55℃之後維持1小時。In some embodiments, the aqueous solvent may further comprise amylase. In some embodiments, the heating procedure S02 refers to stirring and mixing the pineapple custard raw material with water and starch saccharifying enzyme sufficiently, and then raising it to 50° C. to 100° C. for a period of time. Among them, the content of active ingredients in the pineapple chardonnay extract can be further increased by the fermentation of enzymes. In some embodiments, the amylase may be at least one of alpha-amylase, beta-amylase, glucoamylase, isoamylase, or a mixture thereof. In some embodiments, the amylinase can be glucoamylase (
在一些實施例中,過濾程序S04是指將加熱後(或降溫後)的鳳梨釋迦原料及溶劑通過篩網以將溶劑內的固體濾除形成過濾液。舉例而言,篩網可以是400網目(mesh)的篩網。In some embodiments, the filtering procedure S04 refers to passing the heated (or cooled) pineapple custard raw material and the solvent through a screen to filter out the solids in the solvent to form a filtrate. For example, the screen may be a 400 mesh screen.
參考圖2。在一些實施例中,加熱程序S02與過濾程序S04之間還包括二次加熱程序S03,二次加熱程序S03是指將經加熱程序S02後的鳳梨釋迦原料,進行二次加熱,其中該二次加熱之溫度高於加熱程序S02之溫度。舉例而言,加熱程序S02之溫度為65℃持續30分鐘,二次加熱程序S03之溫度為95℃持續50分鐘。Refer to Figure 2. In some embodiments, a secondary heating procedure S03 is further included between the heating procedure S02 and the filtering procedure S04, and the secondary heating procedure S03 refers to the secondary heating of the pineapple sago raw material after the heating procedure S02, wherein the secondary heating procedure The heating temperature is higher than the temperature of the heating program S02. For example, the temperature of the heating procedure S02 is 65° C. for 30 minutes, and the temperature of the secondary heating procedure S03 is 95° C. for 50 minutes.
在一些實施例中,濃縮程序S05是指將過濾程序S04所得到的過濾液進行減壓濃縮(廠牌/型號:BUCHI -Rotavapor R-100)以得到初萃液。在一些實施例中,濃縮程序S05所得的初萃液可即為鳳梨釋迦萃取物。在濃縮程序S05的一些實施例中,在40℃~70℃之間進行減壓濃縮。舉例而言,鳳梨釋迦萃取物是將鳳梨釋迦原料依序進行粉碎程序S01、加熱程序S02、過濾程序S04及濃縮程序S05後得到。In some embodiments, the concentration procedure S05 means that the filtrate obtained in the filtration procedure S04 is concentrated under reduced pressure (brand/model: BUCHI-Rotavapor R-100) to obtain a primary extract. In some embodiments, the primary extract obtained in the concentration process S05 may be the extract of pineapple chard. In some embodiments of the concentration procedure S05, the concentration under reduced pressure is performed between 40°C and 70°C. For example, the pineapple custard extract is obtained by sequentially performing the crushing process S01, the heating process S02, the filtration process S04 and the concentration process S05 on the pineapple custard raw material.
在另一些實施例中,濃縮程序S05則是將過濾程序S04所得到的濾液進行減壓濃縮以得到濃縮液。In other embodiments, the concentration procedure S05 is to concentrate the filtrate obtained in the filtration procedure S04 under reduced pressure to obtain a concentrate.
在一些實施例中,濃縮程序S05之後更包括再過濾程序S06是指將濃縮液通過400網目(mesh)的篩網以將濃縮液內的固形物濾除形成鳳梨釋迦萃取物。舉例而言,鳳梨釋迦萃取物是將鳳梨釋迦原料依序進行粉碎程序S01、加熱程序S02、二次加熱程序S03、過濾程序S04、濃縮程序S05及再過濾程序S06後得到。In some embodiments, after the concentration process S05, a re-filtration process S06 is further included, which means passing the concentrated solution through a 400-mesh screen to filter out the solids in the concentrated solution to form the pineapple chardonnay extract. For example, the pineapple custard extract is obtained by performing the crushing procedure S01, the heating procedure S02, the secondary heating procedure S03, the filtration procedure S04, the concentration procedure S05 and the re-filtering procedure S06 in sequence on the pineapple saccharin raw material.
在一些實施例中,鳳梨釋迦萃取物用於製備肌膚美白組合物之用途,其中鳳梨釋迦萃取物是透過抑制酪胺酸酶活性、或減少細胞黑色素生成以達到肌膚酶美白,且鳳梨釋迦萃取物是以一種含水之溶劑進行萃取。在一些實施例中該細胞黑色素生成係源自紫外線照射所產生。在一些實施例中,該紫外線為UVA。In some embodiments, the use of the pineapple chamomile extract for preparing a skin whitening composition, wherein the pineapple chamomile extract achieves skin enzymatic whitening by inhibiting tyrosinase activity or reducing the production of melanin in cells, and the pineapple chakra extract Extraction is carried out with an aqueous solvent. In some embodiments the cellular melanogenesis is generated from ultraviolet radiation. In some embodiments, the ultraviolet light is UVA.
肌膚之所以會呈現較深的顏色係因黑色素之生成,而在黑色素生成的過程中,酪胺酸酶(Tyrosinase)佔據舉足輕重之地位。酪胺酸酶是一種氧化酶,係調控黑色素生成的限速酶。具體而言,酪胺酸酶參與了黑色素合成的兩個反應:(1) 將單酚羥基化為二酚,(2) 將鄰二酚氧化為鄰二醌。酪胺酸酶係存在於皮膚黑色素細胞中,係由TYR基因轉錄所形成。因此,透過酪胺酸酶活性的抑制,可以達到減少黑色素之生成,以達到肌膚美白之功效。The darker color of the skin is due to the production of melanin, and in the process of melanin production, tyrosinase plays an important role. Tyrosinase is an oxidase, the rate-limiting enzyme that regulates melanin production. Specifically, tyrosinase is involved in two reactions in melanin synthesis: (1) hydroxylation of monophenols to diphenols and (2) oxidation of ortho-diphenols to ortho-diquinones. Tyrosinase is present in skin melanocytes and is formed by the transcription of TYR gene. Therefore, through the inhibition of tyrosinase activity, the production of melanin can be reduced to achieve the effect of skin whitening.
在一些實施例中,鳳梨釋迦萃取物可以透過抑制酪胺酸酶之形成以達到抑制、預防或減緩肌膚黑色素之形成,進而達到肌膚美白及/或提升肌膚光澤之功效。In some embodiments, the pineapple charcoal extract can inhibit, prevent or slow down the formation of melanin in the skin by inhibiting the formation of tyrosinase, thereby achieving the effect of skin whitening and/or enhancing skin radiance.
在一些實施例中,濃度為0.5 mg/mL以上的鳳梨釋迦萃取物可以用於提升肌膚光澤及/或提升肌膚之白皙程度。In some embodiments, the extract of pineapple chard at a concentration of 0.5 mg/mL or more can be used to enhance skin radiance and/or improve skin fairness.
在一些實施例中,白利糖度(Degrees Brix)值為8.0以上的鳳梨釋迦萃取物可以用於提升肌膚光澤及/或提升肌膚之白皙程度。In some embodiments, pineapple sacha extract with a Degrees Brix value of 8.0 or higher can be used to enhance skin radiance and/or improve skin fairness.
在一些實施例中,鳳梨釋迦萃取物用於製備提升肌膚抵禦紫外線能力之組合物之用途,其中鳳梨釋迦萃取物是透過提升細胞內粒線體活性以達到肌膚抵禦紫外線能力,且該鳳梨釋迦萃取物是以一種含水之溶劑進行萃取。在一些實施例中,該鳳梨釋迦萃取物係透過提升粒線體活性相關基因以達到該粒線體活性之提升。In some embodiments, the pineapple chamomile extract is used to prepare a composition for enhancing the skin's ability to resist ultraviolet rays, wherein the pineapple chardonnay extract achieves the skin's ability to resist ultraviolet rays by enhancing the activity of intracellular mitochondria, and the pineapple chakra extract The material is extracted with an aqueous solvent. In some embodiments, the pineapple chardonnay extract achieves the enhancement of mitochondrial activity by enhancing mitochondrial activity-related genes.
在一些實施例中,粒線體活性相關基因為PARP1基因(Gene ID: 142)、PARP2(Gene ID: 10038)及NADSYN(Gene ID: 55191)。In some embodiments, the mitochondrial activity-related genes are the PARP1 gene (Gene ID: 142), PARP2 (Gene ID: 10038), and NADSYN (Gene ID: 55191).
其中, PARP1基因與PARP2基因各自所轉錄之蛋白質PARP1與PARP2具有抑制NAD+的功能,因此若該些基因表現降低,NAD+的含量將提升。而NAD+是提供細胞能量的分子,可用於代謝、構建新的細胞、抵抗自由基和DNA損傷等,其亦協助粒線體產生身體維持功能所需的能量。因此,透過PARP1與PARP2的抑制,粒線體可保持較佳活性,除了能增加個體之體力亦可減緩細胞衰老或死亡。而PARP1為PARP家族的主要組成,PARP2則較為輔助性的腳色,其可在PARP1喪失功能後作為替補使用。Among them, the proteins PARP1 and PARP2 transcribed by the PARP1 gene and the PARP2 gene have the function of inhibiting NAD+, so if the expression of these genes is reduced, the content of NAD+ will increase. NAD+ is a molecule that provides cellular energy, which can be used for metabolism, building new cells, resisting free radicals and DNA damage, etc. It also assists the mitochondria to generate the energy needed for the body to maintain functions. Therefore, through the inhibition of PARP1 and PARP2, the mitochondria can maintain a better activity, in addition to increasing the physical strength of the individual, it can also slow down cell senescence or death. While PARP1 is the main component of the PARP family, PARP2 is a more auxiliary role, which can be used as a substitute after PARP1 loses its function.
NADSYN則為NAD合成路徑重要的催化因子,其主要作用是將NaAD催化為NAD。而如上所述,NAD是身體產生能量的重要分子,因此透過NADSYN基因表現量的提升,粒線體活性將增加,進而提升細胞存活率。NADSYN is an important catalytic factor in the NAD synthesis pathway, and its main role is to catalyze NaAD to NAD. As mentioned above, NAD is an important molecule for the body to generate energy. Therefore, by increasing the expression of NADSYN gene, mitochondrial activity will increase, thereby improving cell survival.
換言之,鳳梨釋迦萃取物可藉由提高上述基因表現量,提升肌膚粒線體之活性、進而提升肌膚抵禦紫外線之能力。In other words, Pineapple Shakya extract can enhance the activity of the skin mitochondria by increasing the expression of the above-mentioned genes, thereby enhancing the ability of the skin to resist ultraviolet rays.
在一些實施例中,濃度為0.5 mg/mL以上的鳳梨釋迦萃取物可以提升肌膚抵禦紫外線之能力。In some embodiments, the extract of pineapple custard at a concentration of more than 0.5 mg/mL can improve the skin's ability to resist ultraviolet rays.
在一些實施例中,白利糖度(Degrees Brix)值為8.0以上的鳳梨釋迦萃取物可以提升肌膚抵禦紫外線之能力。In some embodiments, the pineapple sacha extract with a Degrees Brix value of 8.0 or higher can improve the skin's ability to resist UV rays.
在一些實施例中,鳳梨釋迦萃取物可以用於製備提升肌膚彈性之用途。In some embodiments, the extract of pineapple charcoal can be used to improve skin elasticity.
在一些實施例中,該鳳梨釋迦萃取物係透過提升肌膚細胞之彈力蛋白分泌能力,以達到肌膚彈性之提升。In some embodiments, the Pineapple Shakya extract improves skin elasticity by enhancing the elastin secretion capacity of skin cells.
在一些實施例中,濃度為0.5 mg/mL以上的鳳梨釋迦萃取物可以提升肌膚彈性,且該鳳梨釋迦萃取物是以一種含水之溶劑進行萃取。In some embodiments, the pineapple custard extract at a concentration of more than 0.5 mg/mL can improve skin elasticity, and the pineapple custard extract is extracted with a water-containing solvent.
在一些實施例中,白利糖度(Degrees Brix)值為8.0以上的鳳梨釋迦萃取物可以提升肌膚彈性。In some embodiments, the pineapple charcoal extract with a Degrees Brix value of 8.0 or higher can improve skin elasticity.
在一些實施例中,前述之組合物可為醫藥品。換言之,此醫藥品包含有有效含量的鳳梨釋迦萃取物。換言之,此醫藥品包含有有效含量的鳳梨釋迦萃取物。In some embodiments, the aforementioned compositions may be pharmaceuticals. In other words, this medicinal product contains an effective amount of pineapple chardonnay extract. In other words, this medicinal product contains an effective amount of pineapple chardonnay extract.
在一些實施例中,前述之醫藥品可利用熟習此技藝者所詳知的技術而被製造成一適合於經腸道或口服的投藥劑型。這些投藥劑型包括,但不限於:錠劑(tablet)、片劑(troche)、口含錠(lozenge)、丸劑(pill)、膠囊(capsule)、分散性粉末(dispersible powder)或細顆粒(granule)、溶液、懸浮液(suspension)、乳劑(emulsion)、糖漿(syrup)、酏劑(elixir)、濃漿(slurry)以及類似之物。In some embodiments, the aforementioned pharmaceutical products can be manufactured into a dosage form suitable for parenteral or oral administration using techniques well known to those skilled in the art. These administration forms include, but are not limited to: tablet, troche, lozenge, pill, capsule, dispersible powder or fine granules ( granule), solution, suspension, emulsion, syrup, elixir, slurry and the like.
在一些實施例中,前述之醫藥品可利用熟習此技藝者所詳知的技術而被製造成一適合於非經腸道地(parenterally)或局部地(topically)投藥的劑型,這些投藥劑型包括,但不限於:注射品(injection)、無菌的粉末(sterile powder)、外部製劑(external preparation)以及類似之物。在一些實施例中,該醫藥品可以一選自於由下列所構成之群組中的非經腸道途徑(parenteral routes)來投藥:皮下注射(subcutaneous injection)、表皮內注射(intraepidermal injection)、皮內注射(intradermal injection)以及病灶內注射(intralesional injection)。In some embodiments, the aforementioned pharmaceutical products can be manufactured into a dosage form suitable for parenterally or topically administration using techniques well known to those skilled in the art, including , but not limited to: injection, sterile powder, external preparation and the like. In some embodiments, the medicinal product may be administered by a parenteral route selected from the group consisting of: subcutaneous injection, intraepidermal injection, Intradermal injection and intralesional injection.
在一些實施例中,醫藥品可進一步包含有被廣泛地使用於藥物製造技術之醫藥上可接受的載劑(pharmaceutically acceptable carrier)。例如,醫藥上可接受的載劑可包含下列的試劑中一種或多種:溶劑(solvent)、緩衝液(buffer)、乳化劑(emulsifier)、懸浮劑(suspending agent)、分解劑(decomposer)、崩解劑(disintegrating agent)、分散劑(dispersing agent)、黏結劑(binding agent)、賦形劑(excipient)、安定劑(stabilizing agent)、螯合劑(chelating agent)、稀釋劑(diluent)、膠凝劑(gelling agent)、防腐劑(preservative)、潤濕劑(wetting agent)、潤滑劑(lubricant)、吸收延遲劑(absorption delaying agent)、脂質體(liposome)以及類似之物。有關這些試劑的選用與數量是落在熟習此項技術之人士的專業素養與例行技術範疇內。In some embodiments, the medicinal product may further comprise a pharmaceutically acceptable carrier that is widely used in pharmaceutical manufacturing techniques. For example, a pharmaceutically acceptable carrier may contain one or more of the following agents: solvent, buffer, emulsifier, suspending agent, decomposer, disintegrating agent Disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling gelling agents, preservatives, wetting agents, lubricants, absorption delaying agents, liposomes, and the like. The selection and quantity of these reagents are within the scope of the expertise and routine skills of those skilled in the art.
在一些實施例中,醫藥上可接受的載劑包含有一選自於由下列所構成之群組中的溶劑:水、生理鹽水(normal saline)、磷酸鹽緩衝生理鹽水(phosphate buffered saline, PBS)、含有醇的水性溶液(aqueous solution containing alcohol)。In some embodiments, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS) , An aqueous solution containing alcohol.
在一些實施例中,前述之組合物可為可食用組合物。在一些實施例中,此可食用組合物可以製成食品產品或可為食品添加物(food additive),意即藉由習知方法於食材製備時添加而製得食品產品,或是於食品產品的製作過程中添加。於此,食品產品可以是與可食性材料配製成供人類或動物攝食的產品。In some embodiments, the aforementioned compositions may be edible compositions. In some embodiments, the edible composition can be made into a food product or can be a food additive, meaning that it is added to the food product by conventional methods during the preparation of the food product, or can be added to the food product added during the production process. Here, the food product may be a product formulated with an edible material for ingestion by humans or animals.
在一些實施例中,食品產品可為但不限於:飲料(beverages)、發酵食品(fermented foods)、烘培產品(bakery products)、健康食品(health foods)以及膳食補充品(dietary supplements)。In some embodiments, food products may be, but are not limited to, beverages, fermented foods, bakery products, health foods, and dietary supplements.
[[ 例example 1]1] 鳳梨釋迦萃取物之製備Preparation of Pineapple Shakyamuni Extract
將鳳梨釋迦的果實經粉碎(Osterizer 品牌的10 speed blender)並以10目數(mesh)的篩網將其過篩,去除過大顆粒後取得鳳梨釋迦果實粗碎物。在另一些實施例中,篩網的目數可為8目或12目。The fruit of Pineapple Sakyamuni was crushed (10 speed blender of Osterizer brand) and sieved with a 10-mesh sieve to remove excessively large particles to obtain coarsely crushed Pineapple Sakyamuni fruit. In other embodiments, the mesh number of the screen may be 8 or 12 mesh.
接著,加熱程序中,以水為溶劑與鳳梨釋迦果實粗碎物以5:1的重量比混合,加入混合液0.1wt%之澱粉糖化酵素並於55 ±5℃下萃取約60分鐘以形成含有固體的第一萃取液。於此,採用市售AMG品牌的300L酵素。Next, in the heating process, use water as a solvent to mix with the coarsely crushed pineapple custard fruit at a weight ratio of 5:1, add 0.1 wt% starch saccharifying enzyme in the mixture, and extract at 55±5°C for about 60 minutes to form a mixture containing Solid first extract. Here, the commercially available AMG brand 300L enzyme was used.
在另一些實施例中,溶劑與鳳梨釋迦果實的重量比亦可為10:1~20:1,浸泡時的溫度可為45℃-75℃,萃取時間可為30-90分鐘。若溶劑過少或萃取時間過短,則萃取效率將會明顯下降;若萃取時間過長,則萃取物中的有效成分可能會產生降解。In other embodiments, the weight ratio of the solvent to the pineapple sakya fruit can also be 10:1-20:1, the soaking temperature can be 45°C-75°C, and the extraction time can be 30-90 minutes. If the solvent is too small or the extraction time is too short, the extraction efficiency will drop significantly; if the extraction time is too long, the active ingredients in the extract may be degraded.
將前述第一萃取液進行二次加熱,該加熱溫度為85 ±5℃,並以此溫度維持60分鐘,以形成第二萃取液,其中該第二萃取液之Brix值大於2.5。The aforementioned first extraction solution is heated twice, and the heating temperature is 85±5° C. and maintained at this temperature for 60 minutes to form a second extraction solution, wherein the Brix value of the second extraction solution is greater than 2.5.
將前述第二萃取液進行過濾,以濾除較大之固形物,其中該過濾所使用之篩網為400網目(mesh)的篩網。The aforesaid second extract is filtered to remove larger solids, wherein the sieve used in the filtration is a 400-mesh sieve.
將過濾後之濾液以濃縮機(廠牌/型號:BUCHI -Rotavapor R-100),在60℃±5℃下進行減壓濃縮至溶液的白利糖度值(Degrees Brix)為8±0.5時停止濃縮,得到本案之鳳梨釋迦萃取物。在另一些實施例中,可於45℃-70℃下進行減壓濃縮。The filtered filtrate was concentrated under reduced pressure with a concentrator (brand/model: BUCHI -Rotavapor R-100) at 60°C ± 5°C until the solution's Brix value (Degrees Brix) was 8 ± 0.5. Concentrated to obtain the Pineapple Shakyamuni extract of this case. In other embodiments, the concentration under reduced pressure can be performed at 45°C-70°C.
[[ 例example 2]2] 多醣定量實驗Polysaccharide Quantitative Experiment
標準曲線繪製:Standard curve drawing:
首先,精密秤取D-葡萄糖(D-Glucose)(購自J.T. Baker,料號:1916-01) 10 mg,置於10 mL 容量瓶中,以二次蒸餾水(ddH2 O)定量至10 mL,配置成1 mg/mL濃度之D-葡萄糖溶液。First, accurately weigh 10 mg of D-Glucose (purchased from JT Baker, part number: 1916-01), put it in a 10 mL volumetric flask, and quantify it to 10 mL with double distilled water (ddH 2 O). , configured into a D-glucose solution with a concentration of 1 mg/mL.
接著,將上述標準品進行系列稀釋,以二次蒸餾水稀釋為0, 20, 50, 100, 150, 200 μg/mL 之D-葡萄糖溶液。可參酌下表1之方式配置標準溶液。Next, the above-mentioned standards were serially diluted to 0, 20, 50, 100, 150, 200 μg/mL of D-glucose solution with double distilled water. The standard solution can be prepared by referring to Table 1 below.
表1:D-葡萄糖溶液標準溶液配置方法
之後,取標準溶液各100 μL放置於玻璃試管中,再各加入500μL濃度為5%的苯酚溶液(Phenol)(購自Merck,料號:1.00206.0250)。After that, 100 μL of each standard solution was placed in a glass test tube, and 500 μL of 5% phenol solution (Phenol) (purchased from Merck, part number: 1.00206.0250) was added to each.
接著緩慢加入2.5 mL濃度為95.5%,比重1.84之濃硫酸溶液(H2 SO4 )(購自Showa,料號:1970-5250)。經由渦旋(vortex)確保無氣泡後,靜置20分鐘。最後,取200 μL樣品放入96孔培養盤,於490 nm下測定其吸光值,並繪製標準曲線。Then, 2.5 mL of concentrated sulfuric acid solution (H 2 SO 4 ) with a concentration of 95.5% and a specific gravity of 1.84 (purchased from Showa, part number: 1970-5250) was slowly added. After ensuring no air bubbles by vortexing, it was left to stand for 20 minutes. Finally, 200 μL of the sample was taken into a 96-well culture plate, and its absorbance value was measured at 490 nm, and a standard curve was drawn.
樣品總多醣定量實驗:Sample total polysaccharide quantification experiment:
另外,將例1所得的鳳梨釋迦萃取物與水稀釋20倍至1200μL並取100μL的體積至玻璃試管中,每組樣品需三重複。之後,加入500 μL 濃度為5%的苯酚溶液(Phenol)(購自Merck,料號:1.00206.0250)。In addition, dilute the pineapple chamomile extract obtained in Example 1 with water 20 times to 1200 μL and take a volume of 100 μL into a glass test tube, and each group of samples needs to be repeated three times. After that, 500 μL of 5% phenol solution (Phenol) (available from Merck, Cat. No. 1.00206.0250) was added.
接著緩慢加入2.5 mL濃度為95.5%,比重1.84之濃硫酸溶液(H2 SO4 )(購自Showa,料號:1970-5250)。經由渦旋(vortex)確保無氣泡後,靜置20 分鐘。最後,取200 μL樣品放入96孔培養盤,於490 nm下測定其吸光值,並以內插法算出濃度後再乘回稀釋倍數以取得原萃取液濃度。Then, 2.5 mL of concentrated sulfuric acid solution (H 2 SO 4 ) with a concentration of 95.5% and a specific gravity of 1.84 (purchased from Showa, part number: 1970-5250) was slowly added. After ensuring no air bubbles by vortexing, it was left to stand for 20 minutes. Finally, 200 μL of sample was taken into a 96-well culture plate, and its absorbance value was measured at 490 nm, and the concentration was calculated by interpolation and then multiplied back to the dilution factor to obtain the concentration of the original extract.
實驗結果:Experimental results:
根據前述實驗之結果,本發明之鳳梨釋迦多醣含量為50000 ppm。According to the results of the above-mentioned experiments, the content of pineapple polysaccharide in the present invention is 50,000 ppm.
[ 例 3] 細胞實驗 - 抑制酪胺酸酶活性 [ Example 3 ] Cell experiment - inhibition of tyrosinase activity
酪胺酸酶是生物體內黑色素合成的關鍵,酪胺酸酶會催化酪胺酸轉變為L-Dopa,接著產生Dopaquinone進而形成黑色素。於此,藉由檢測酪胺酸酶活性來了解鳳梨釋迦萃取物對於黑色素細胞產生黑色素的能力影響,當酪胺酸酶活性低時,黑色素細胞產生黑色素的能力就會相對降低。Tyrosinase is the key to melanin synthesis in living organisms. Tyrosinase catalyzes the conversion of tyrosine into L-Dopa, and then produces Dopaquinone to form melanin. Here, the tyrosinase activity was detected to understand the effect of pineapple sacha extract on the ability of melanocytes to produce melanin. When the tyrosinase activity was low, the ability of melanocytes to produce melanin was relatively reduced.
材料與儀器
1. 細胞株:小鼠黑色素瘤細胞B16F10,購自美國典型培養物保存中心(American Type CμLtureCollection,ATCC®
,No.6475),以下簡稱B16F10細胞。
2. 培養基:將DMEM改良培養基(Dulbecco’s modified Eagle’s medium,DMEM,購自Gibco,Cat. 12100-038)添加額外成分使其含有10 vol% FBS(fetal bovine Serum,購自Gibco,10438-026)及1% 青黴素-鏈黴素 (購自Gibco,Cat. 15140122)。
3. 磷酸緩衝鹽溶液(PBS溶液):購自Gibco,產品編號10437-028。
4. 麴酸(Kojic acid):購自Sigma-Aldrich,產品編號K3125-5G。
5. 全稱放射免疫沉澱法緩衝液蛋白質裂解液(RIPA Lysis Buffer (PMSF)):購自Sigma-Aldrich,產品編號10837091001。
6. Bio-rad Protein Assay,購自Biotek,產品編號Epoch。
7. 10 mM L-多巴(L-Dopa):將9.8 mg 的 L-多巴(購自Sigma-Aldrich,產品編號D9628-5G。)溶於5mL的0.1mM,pH值7.0的PBS溶液中。
8. 胰蛋白酶:10X Trypsin-EDTA(購自Gibco)以1X PBS溶液稀釋10倍。
9. 鳳梨釋迦萃取物:由本案例1之製備方式所製得。Materials and
實驗步驟:Experimental steps:
於每一孔中加入2mL上述培養基,並將B16F10細胞以1.5 x 105 的每孔密度種入一6孔盤中,於37°C下,培養24小時。2 mL of the above medium was added to each well, and B16F10 cells were seeded in a 6-well dish at a density of 1.5 x 10 5 per well and incubated at 37°C for 24 hours.
本實驗分為控制組、對照組、實驗組。其中,各組加入2mL的新鮮DMEM培養液。而對照組之培養液額外加入麴酸(Kojic acid),使其濃度為0.5 mg/mL,其中麴酸已被廣泛認知為具有抑制細胞酪胺酸酶活性之物質;實驗組之培養液額外加入鳳梨釋迦萃取物,使其濃度為0.5 mg/mL。各組進行三重複,並反應培養48小時。The experiment was divided into control group, control group and experimental group. Among them, 2 mL of fresh DMEM medium was added to each group. In the culture medium of the control group, Kojic acid was additionally added to a concentration of 0.5 mg/mL. Kojic acid has been widely recognized as a substance that inhibits cellular tyrosinase activity; the culture medium of the experimental group was additionally added with kojic acid. Pineapple Sakya extract to a concentration of 0.5 mg/mL. Three replicates were performed for each group, and the reaction was incubated for 48 hours.
培養完畢後,將培養液移除,以1x PBS(Gibco)清洗兩次。再加入胰蛋白酶-EDTA對細胞作用3分鐘,回收懸浮的細胞於15 mL離心管,以400 xg離心5分鐘使細胞沉澱。After incubation, the medium was removed and washed twice with 1x PBS (Gibco). Then trypsin-EDTA was added to act on the cells for 3 minutes, the suspended cells were recovered in a 15 mL centrifuge tube, and the cells were pelleted by centrifugation at 400 xg for 5 minutes.
再將沉澱細胞以1x PBS清洗兩次後,以200 μL細胞裂解液讓細胞懸浮,震盪混合後以12,000 xg離心20分鐘。After the pelleted cells were washed twice with 1x PBS, the cells were suspended with 200 μL of cell lysate, mixed by shaking, and centrifuged at 12,000 x g for 20 minutes.
將上清液取出至1.5 mL離心管中,進行蛋白質濃度的檢測:Remove the supernatant into a 1.5 mL centrifuge tube for protein concentration detection:
先將Bio-rad染劑與去離子水混合(體積比為1:4),分裝500 μL至微量離心管中。而後,分別於前述微量離心管中,加入10、8、6、4、2、1與0 μL 2mg/mL的BSA以製備標準濃度蛋白質。再加入2 μL測試樣本進行檢測。取出前述反應後之測試樣本200 μL於96孔盤中,以ELISA讀取儀(BioTek)測定595 nm的吸光值。First, mix Bio-rad stain with deionized water (1:4 by volume), and dispense 500 μL into microcentrifuge tubes. Then, 10, 8, 6, 4, 2, 1, and 0 μL of 2 mg/mL BSA were added to the aforementioned microcentrifuge tubes to prepare standard protein concentration. Add another 2 μL of test sample for detection. 200 μL of the test sample after the above reaction was taken out in a 96-well plate, and the absorbance at 595 nm was measured with an ELISA reader (BioTek).
接著,於每孔中加入400 μg蛋白質,再加入90 μL細胞裂解液,包括控制組及對照組。在避光環境下,在37°C下加入10 μL10M的L-Dopa,每10分鐘觀察一次,直到懸浮液變黑。之後再測定405 nm的吸光值。Next, 400 μg of protein was added to each well, followed by 90 μL of cell lysate, including control group and control group. In the dark, add 10 μL of 10 M L-Dopa at 37 °C and observe every 10 min until the suspension turns black. The absorbance at 405 nm was then measured.
酪胺酸酶含量的分析公式為:酪胺酸酶抑制性(%)=(樣本吸光值/控制組吸光值)×100%。所得數值再以微軟EXCEL軟體,利用Student t檢定進行統計分析,其結果如圖3所示。The analytical formula for tyrosinase content is: tyrosinase inhibition (%) = (sample absorbance value/control group absorbance value) × 100%. The obtained values were then statistically analyzed with Microsoft EXCEL software and Student's t test, and the results are shown in Figure 3.
實驗結果:Experimental results:
由圖3之結果可知,在本發明之鳳梨釋迦萃取物的處理下,可達到抑制酪胺酸酶活性的功效。具體而言,對照組相對控制組之酪胺酸酶活性為79.66%,實驗組(鳳梨釋迦萃取物)相對控制組之酪胺酸酶活性為67.88%,由此可知,本案鳳梨釋迦萃取物於抑制酪胺酸之功效更甚於麴酸之抑制酪胺酸酶活性效果。因此,藉由本發明實施例所製備之鳳梨釋迦萃取物,確實可降低酪胺酸酶活性,進而可減少黑色素的生成,故可應用於減少皮膚黑斑、提升肌膚光澤、白皙度肌膚美白的相關組合物的成分中。It can be seen from the results in FIG. 3 that the effect of inhibiting the activity of tyrosinase can be achieved under the treatment of the pineapple chardonnay extract of the present invention. Specifically, the tyrosinase activity of the control group relative to the control group was 79.66%, and the tyrosinase activity of the experimental group (Pineapple Sakyamuni extract) relative to the control group was 67.88%. It can be seen that the Pineapple Sakyamuni extract in this case is in The effect of inhibiting tyrosine is stronger than that of koji acid. Therefore, the pineapple chamomile extract prepared by the embodiment of the present invention can indeed reduce the activity of tyrosinase, thereby reducing the production of melanin, so it can be applied to reduce skin dark spots, improve skin luster, and whiteness and skin whitening. components of the composition.
[ 例 4] 細胞實驗 - 鳳梨釋迦萃取物降低黑色素生成 [ Example 4 ] Cell Experiment - Pineapple Shakyamuni Extract Reduces Melanin Production
於此,以ELISA讀盤機(enzyme-linked immunosorbent assay reader)測定黑色素瘤細胞株B16F10經鳳梨釋迦萃取物處理後,其黑色素含量的變化。Here, the changes of the melanin content of the melanoma cell line B16F10 after being treated with the extract of pineapple chardonnay were measured by an enzyme-linked immunosorbent assay reader.
材料與儀器
1. 細胞株:小鼠黑色素瘤細胞B16F10,購自美國典型培養物保存中心(American Type CμLtureCollection,ATCC®,No.6475),以下簡稱B16F10細胞。
2. 培養基:將Dulbecco's modified minimal essential medium(DMEM,購自Gibco,Cat. 12100-038)添加額外成分使其含有1 vol%的抗生素溶液(Antibiotic Antimycotic Solution,購自Gibco,15240-062)及10 vol%的FBS(fetal bovine Serum,購自Gibco,10437-028)。
3. 磷酸緩衝鹽溶液(PBS溶液):購自Gibco,產品編號10437-028。
4. 以二次蒸餾水配製1N NaOH(購自Sigma,產品編號221465)溶液。
5. ELISA reader(購自BioTek,產品編號FLx 800)。
6. 鳳梨釋迦萃取物:由本案例1之製備方式所製得。Materials and
實驗步驟Experimental procedure
實驗將會分為實驗組、控制組及對照組三組進行,各組分別進行三重複試驗: 1. 將B16F10細胞以每孔1.5×105 個的方式,接種於每孔含3ml培養基之6孔培養盤中。 2. 將培養盤置於5%CO2 、37℃環境下,培養24小時。 3. 而後,在不干擾附著細胞的情況下,移除每孔之培養基。 4. 本實驗分為控制組、對照組、實驗組。其中,各組加入2mL的新鮮DMEM培養液。而對照組之培養液額外加入麴酸(Kojic acid),使其濃度為0.5 mg/mL,其中麴酸已被廣泛認知為具有降低黑色素生成效果之物質;實驗組之培養液額外加入例1之鳳梨釋迦萃取物,使其濃度為0.5mg/mL。各組進行三重複,並使其於37℃下培養24小時。 5. 將反應完畢之實驗組及對照組移至藍光箱中,使其在室溫(25±5℃)下接受藍光照射3小時。另外,控制組移至暗室中,使其在室溫下靜置3小時。 6. 反應後,將細胞於37℃下培養48小時。 7. 而後,移除培養基,並以PBS溶液清洗細胞2次。 8. 將200μl胰蛋白酶(Trypsin-EDTA (10X),購自Gibco;產品編號15400-054)加至每孔中反應3分鐘。反應後,添加6 mL培養基溶液終止反應。而後收集各孔中之懸浮細胞與培養基至對應的15ml離心試管內,將各離心試管以400 xg離心5分鐘使細胞沉澱。 9. 以PBS溶液清洗沉澱細胞二次後,再以200μL PBS溶液重新懸浮細胞。 10. 將細胞懸浮液以液態氮冷凍10分鐘,再置於室溫約30分鐘至完全解凍。 11. 完全解凍後,將試管以12,000g離心3分鐘。 12. 移除上清液,再以120μL 1N氫氧化鈉溶液重新懸浮細胞沉澱後,使試管於60℃乾浴1小時,以獲得待檢測樣本。 13. 將100μL待檢測樣本移入一96孔盤,使用ELISA讀盤機測量細胞溶液在450nm的吸光值。The experiment will be divided into three groups: the experimental group, the control group and the control group. Each group will conduct three replicate experiments: 1. B16F10 cells are inoculated into 6 cells containing 3 ml of medium in each well in the form of 1.5×10 5 cells per well. well in the culture dish. 2. Incubate the plate in 5% CO 2 at 37°C for 24 hours. 3. Then, without disturbing the attached cells, remove the medium from each well. 4. This experiment is divided into control group, control group and experimental group. Among them, 2 mL of fresh DMEM medium was added to each group. The culture medium of the control group was additionally added with kojic acid to make the concentration of 0.5 mg/mL, among which kojic acid has been widely recognized as a substance that has the effect of reducing melanin production; the culture medium of the experimental group was additionally added with Example 1 Pineapple Shakya extract, so that the concentration is 0.5mg/mL. Groups were replicated in triplicate and incubated at 37°C for 24 hours. 5. Move the experimental group and the control group after the reaction to a blue light box, and let them receive blue light irradiation at room temperature (25±5℃) for 3 hours. Additionally, the control group was moved to a dark room and allowed to stand at room temperature for 3 hours. 6. After the reaction, the cells were incubated at 37°C for 48 hours. 7. Then, remove the medium and wash the cells twice with PBS solution. 8. Add 200 μl trypsin (Trypsin-EDTA (10X), available from Gibco; Product No. 15400-054) to each well for 3 minutes. After the reaction, 6 mL of medium solution was added to stop the reaction. Then, the suspended cells and medium in each well were collected into corresponding 15ml centrifuge tubes, and each centrifuge tube was centrifuged at 400 xg for 5 minutes to pellet the cells. 9. After washing the pelleted cells twice with PBS, resuspend the cells with 200 μL of PBS. 10. Freeze the cell suspension in liquid nitrogen for 10 minutes and allow to thaw completely at room temperature for about 30 minutes. 11. After complete thawing, centrifuge the tube at 12,000g for 3 minutes. 12. Remove the supernatant, resuspend the cell pellet with 120 μL of 1N sodium hydroxide solution, and dry the test tube at 60°C for 1 hour to obtain the sample to be tested. 13. Transfer 100 μL of the sample to be tested into a 96-well plate, and use an ELISA plate reader to measure the absorbance of the cell solution at 450 nm.
實驗結果Experimental results
實驗組以及控制組的黑色素相對表現量係依下列公式計算:黑色素相對表現量(%)=(各組OD450 值/控制組OD450 值)×100%。因實驗係進行三重複,故將三重複實驗之結果平均後,顯示於圖4。The relative expression of melanin in the experimental group and the control group was calculated according to the following formula: relative expression of melanin (%)=(OD 450 value of each group/OD 450 value of control group)×100%. Since the experiment was performed in triplicate, the results of the triplicate experiments were averaged and shown in Figure 4 .
如圖4所示,在本發明之鳳梨釋迦萃取物的處理下,可達到降低黑色素生成的功效。具體而言,對照組相對控制組之黑色素生成量為79.32%,實驗組(鳳梨釋迦萃取物)相對控制組之黑色素生成量為81.01%,亦即實驗組與控制組相比黑色素生成降低約18.99%,且本案鳳梨釋迦萃取物之功效近似於麴酸之降低黑色素生成之效果。因此,本發明實施例所製備之鳳梨釋迦萃取物,確實可有效減少黑色素細胞所生成之黑色素,故可應用於減少皮膚黑斑、提升肌膚光澤、白皙度肌膚美白的相關組合物的成分中。As shown in FIG. 4 , the effect of reducing the production of melanin can be achieved under the treatment of the Pineapple Sakyamuni extract of the present invention. Specifically, the production of melanin in the control group was 79.32% relative to the control group, and the production of melanin in the experimental group (Pineapple Sakyamuni extract) relative to the control group was 81.01%, that is, the production of melanin in the experimental group was reduced by about 18.99% compared with the control group %, and the effect of the pineapple sacha extract in this case is similar to the effect of kojic acid in reducing the production of melanin. Therefore, the pineapple chamomile extract prepared in the embodiment of the present invention can indeed effectively reduce the melanin produced by melanocytes, so it can be used as an ingredient in a related composition for reducing skin dark spots, enhancing skin radiance, and whitening skin.
[ 例 5] 細胞實驗 - 鳳梨釋迦萃取物 抵抗與防禦 UVA 能力 [ Example 5 ] Cell Experiment - Anti- UVA Ability of Pineapple Sakya Extract
於此測定人類皮膚纖維母細胞CCD-966sk經鳳梨釋迦萃取物處理後,其抵抗UVA之能力。Here, the ability of human dermal fibroblasts CCD-966sk to resist UVA after treatment with pineapple charcoal extract was determined.
材料與儀器
1. 細胞株:人類皮膚纖維母細胞(Human skin fibroblast)CCD-966sk(生物資源保存及研究中心(BCRC),No. 60153)。
2. 培養基:將Eagle’s最低限度基本培養基(minimum essential medium,MEM,購自Gibco,15188-319)添加額外成分使其含有10 vol% FBS(fetal bovine Serum,購自Gibco,10437-028)、90 vol% 1mM 丙酮酸鈉(sodium pyruvate,購自Gibco,11360-070)、1.5g/L 碳酸氫鈉(購自Sigma)、0.1mM 非必需胺基酸(non-essential amino acid solution,購自Gibco,11140-050)。
3. 磷酸緩衝鹽溶液(PBS溶液):購自Gibco,產品編號10437-028。
4. DMSO溶液:購自ECHO,產品編號DA1101-000000-72EC。
5. MTT溶液:購自Amresco,產品編號0793。
6. 紫外線鏈結箱:購自Cleaver Scientific,產品編號CL-508。
7. EpochTM
微孔板分光光度計:購自BioTek。
8. 倒立式顯微鏡搭載照相系統:購自ZEISS,產品編號:Vert.A1。
9. 本發明之鳳梨釋迦萃取物:此實驗中所使用的鳳梨釋迦萃取物,係以例1之方式製備而成。Materials and
實驗步驟Experimental procedure
實驗將會分為實驗組、控制組(未添加鳳梨釋迦萃取物、亦無經過紫外線照射的組別)、以及對照組(未添加鳳梨釋迦萃取物,但經紫外線照射的組別)三組進行,各組分別進行三重複試驗: 1. 將CCD-966sk細胞以每孔5×103 個的方式,接種於每孔含100ml培養基之96孔培養盤中。 2. 將培養盤置於5%CO2 、37℃下,培養24小時。 3. 移除培養基。 4. 實驗組:添加含有0.625 μL的實施例1得到的鳳梨釋迦萃取物之0.1 mL細胞培養基(即鳳梨釋迦萃取物佔細胞培養基的體積百分比為0.625%),於37℃下,培養24小時。 控制組:添加單純的2 mL細胞培養基(即不含鳳梨釋迦萃取物),於37℃下,培養24小時。 對照組:添加單純的2 mL細胞培養基(即不含鳳梨釋迦萃取物),於37℃下,培養24小時。 5. 實驗組:將培養盤移紫外線鏈結箱,以 12 J/cm2 的 UVA 照射 1 小時。 控制組:將培養盤置於暗處,於室溫下靜置1小時。 對照組:將培養盤移紫外線鏈結箱,以 12 J/cm2 的 UVA 照射 1 小時。 6. 於每孔加入15μl的 MTT溶液,於37℃下,作用4小時。 7. 移除培養液,於每孔加入50μl的DMSO溶液,於軌道震盪器上搖晃10分鐘。 8. 以分光光度計測得O.D.570。 9. 透過以下公式計算細胞存活率: 細胞存活率 (%) = (O.D.UVA /O.D.控制組 )100% 因實驗係進行三重複,故將三重複實驗之結果平均後,顯示於圖5。The experiment will be divided into three groups: the experimental group, the control group (the group without the addition of pineapple sakya extract, and the group without UV irradiation), and the control group (the group without the addition of pineapple saccharomyces extract, but the group exposed to ultraviolet rays). , each group was carried out in three replicates: 1. CCD-966sk cells were seeded in 96-well culture plates containing 100 ml of medium in each well in the form of 5×10 3 cells per well. 2. Incubate the plate in 5% CO 2 at 37°C for 24 hours. 3. Remove the medium. 4. Experimental group: add 0.1 mL of cell culture medium containing 0.625 μL of the pineapple chardonnay extract obtained in Example 1 (that is, the volume percentage of pineapple chardonnay extract in the cell culture medium is 0.625%), and culture at 37°C for 24 hours. Control group: add simple 2 mL cell culture medium (that is, without pineapple extract), and culture at 37°C for 24 hours. Control group: add simple 2 mL cell culture medium (that is, without pineapple sorghum extract), and culture at 37°C for 24 hours. 5. Experimental group: move the culture plate to the UV link box and irradiate it with UVA at 12 J/cm 2 for 1 hour. Control group: The culture plate was placed in a dark place and allowed to stand at room temperature for 1 hour. Control group: The culture plate was moved to the UV link box and irradiated with 12 J/cm 2 of UVA for 1 hour. 6. Add 15 μl of MTT solution to each well and let it act for 4 hours at 37°C. 7. Remove the culture medium, add 50 μl of DMSO solution to each well, and shake on an orbital shaker for 10 minutes. 8. Measure OD570 with a spectrophotometer. 9. Calculate the cell viability by the following formula: Cell viability (%) = (OD UVA /OD control group ) 100% Since the experiment was carried out in triplicate, the results of the triplicate experiments were averaged and shown in Figure 5.
實驗結果Experimental results
如圖5所示,由控制組、對照組的結果可知,在經過紫外線照射後,細胞死亡率增加,顯示紫外光照射確實會導致細胞之存活率降低。另一方面,根據對照組以及實驗組的結果可知,當細胞經過鳳梨釋迦萃取物處理後,其細胞存活率相較於對照組即明顯增加約42.26%,顯示鳳梨釋迦萃取物可有效提升細胞在面對紫外線照射後之存活率,可用於製備一種防禦或抵抗紫外線傷害之組合物。As shown in FIG. 5 , the results of the control group and the control group showed that the cell death rate increased after ultraviolet irradiation, indicating that ultraviolet light irradiation did reduce the survival rate of cells. On the other hand, according to the results of the control group and the experimental group, when the cells were treated with pineapple chardonnay extract, the cell viability was significantly increased by about 42.26% compared with the control group, indicating that the pineapple chardonnay extract can effectively improve the cell survival rate. The survival rate after exposure to ultraviolet rays can be used to prepare a composition for preventing or resisting ultraviolet rays.
[ 例 6] 細胞實驗 - 鳳梨釋迦萃取物降低黑色素生成 [ Example 6 ] Cell Experiment - Pineapple Shakyamuni Extract Reduces Melanin Production
於此,以ELISA讀盤機(enzyme-linked immunosorbent assay reader)測定黑色素瘤細胞株B16F10經鳳梨釋迦萃取物處理後,其黑色素含量的變化。Here, the changes of the melanin content of the melanoma cell line B16F10 after being treated with the extract of pineapple chardonnay were measured by an enzyme-linked immunosorbent assay reader.
材料與儀器
1. 細胞株:小鼠黑色素瘤細胞株B16F10(ATCC CRL-6475),購自美國典型培養物保存中心(American Type Culture Collection,ATCC)。
2. 培養基:將Dulbecco's modified minimal essential medium(DMEM,購自Gibco)添加額外成分使其含有1 vol%的抗生素溶液(Antibiotic Antimycotic Solution,購自Gibco,15240-062)、10 vol%的FBS(fetal bovine Serum,購自Gibco,10437-028)。
3. 磷酸緩衝鹽溶液(PBS溶液):購自Gibco,產品編號10437-028。
4. 以二次蒸餾水配製1N NaOH(購自Sigma,產品編號221465)溶液。
5. ELISA reader(BioTek,FLx 800)。
6. 紫外線(UVA)鏈結箱(VILBER , BLX-254)。
7. 鳳梨釋迦萃取物:此實驗所使用的鳳梨釋迦萃取物係以例1之方式製備而成。Materials and
實驗步驟Experimental procedure
實驗將會分為實驗組、控制組(未添加鳳梨釋迦萃取物、亦無經過UVA照射的組別)、以及對照組(未添加鳳梨釋迦萃取物,但經UVA照射的組別)三組進行,各組分別進行三重複試驗: 1. 將B16F10細胞以每孔1.5×105 個的方式,接種於每孔含3ml培養基之6孔培養盤中。 2. 將培養盤置於5%CO2 、37℃環境下,培養24小時。 3. 而後,在不干擾附著細胞的情況下,移除每孔之培養基。 4. 控制組、對照組、實驗組各組加入2mL的新鮮DMEM培養液。其中,對照組與實驗組之培養液分別額外加入例1之鳳梨釋迦萃取物,使其濃度為0.5 mg/mL。接著,各組均於37℃下培養24小時。 5. 實驗組:將經過鳳梨釋迦萃取物培養基溶液處理步驟的6孔培養盤移至紫外線鏈結箱中,使其在室溫(25±5℃)下接受10 J/cm2 的 UVA 照射,照射3小時。控制組:將6孔培養盤移至暗室中,使其在室溫下靜置3小時。對照組:將6孔培養盤移至紫外線鏈結箱中,使其在室溫下接受10 J/cm2 的 UVA 照射照射3小時。 6. 反應後,將細胞於37℃下培養48小時。 7. 而後,移除培養基,並以PBS溶液清洗細胞2次。 8. 將200μl胰蛋白酶(Trypsin-EDTA (10X),購自Gibco;產品編號15400-054)加至每孔中反應3分鐘。反應後,添加6 mL培養基溶液終止反應。而後收集各孔中之懸浮細胞與培養基至對應的15ml離心試管內,將各離心試管以400 xg離心5分鐘使細胞沉澱。 9. 以PBS溶液清洗沉澱細胞二次後,再以200μL PBS溶液重新懸浮細胞。 10. 將細胞懸浮液以液態氮冷凍10分鐘,再置於室溫約30分鐘至完全解凍。 11. 完全解凍後,將試管以 12,000xg 離心3分鐘。 12. 移除上清液,再以120μL 1N氫氧化鈉溶液重新懸浮細胞沉澱後,使試管於60℃乾浴1小時,以獲得待檢測樣本。 13. 將100μL待檢測樣本移入一96孔盤,使用ELISA讀盤機測量細胞溶液在450nm的光密度值(optical density,OD450 ),作為吸光度。The experiment will be divided into three groups: the experimental group, the control group (the group without the addition of pineapple chardonnay extract, and the group without UVA irradiation), and the control group (the group without the addition of pineapple chardonnay extract, but UVA irradiated). , each group carried out three replicate experiments: 1. B16F10 cells were inoculated in 6-well culture plates containing 3 ml of medium per well at 1.5×10 5 cells per well. 2. Incubate the plate in 5% CO 2 at 37°C for 24 hours. 3. Then, without disturbing the attached cells, remove the medium from each well. 4. Add 2 mL of fresh DMEM medium to the control group, control group and experimental group. Among them, the culture medium of the control group and the experimental group was additionally added with the pineapple sacha extract of Example 1, so that the concentration was 0.5 mg/mL. Then, each group was cultured at 37°C for 24 hours. 5. Experimental group: Move the 6-well culture plate that has undergone the step of pineapple sorghum extract medium solution treatment step to the UV link box, and make it receive 10 J/cm 2 UVA irradiation at room temperature (25±5℃). Irradiated for 3 hours. Control group: The 6-well culture plate was moved to a dark room and allowed to stand at room temperature for 3 hours. Control group: The 6-well culture plate was moved to a UV link box and exposed to 10 J/cm 2 of UVA irradiation for 3 hours at room temperature. 6. After the reaction, the cells were incubated at 37°C for 48 hours. 7. Then, remove the medium and wash the cells twice with PBS solution. 8. Add 200 μl trypsin (Trypsin-EDTA (10X), available from Gibco; Product No. 15400-054) to each well for 3 minutes. After the reaction, 6 mL of medium solution was added to stop the reaction. Then, the suspended cells and medium in each well were collected into corresponding 15ml centrifuge tubes, and each centrifuge tube was centrifuged at 400 xg for 5 minutes to pellet the cells. 9. After washing the pelleted cells twice with PBS, resuspend the cells with 200 μL of PBS. 10. Freeze the cell suspension in liquid nitrogen for 10 minutes and allow to thaw completely at room temperature for about 30 minutes. 11. After complete thawing, centrifuge the tube at 12,000xg for 3 minutes. 12. Remove the supernatant, resuspend the cell pellet with 120 μL of 1N sodium hydroxide solution, and dry the test tube at 60°C for 1 hour to obtain the sample to be tested. 13. Transfer 100 μL of the sample to be tested into a 96-well plate, and use an ELISA plate reader to measure the optical density (OD 450 ) of the cell solution at 450 nm as the absorbance.
實驗結果Experimental results
實驗組、控制組、以及對照組的黑色素相對表現量係依下列公式計算:黑色素相對表現量(%)=(各組OD450 值/控制組OD450 值)×100%。因實驗係進行三重複,故將三重複實驗之結果平均後,顯示於圖6。The relative expression of melanin in the experimental group, the control group, and the control group was calculated according to the following formula: relative expression of melanin (%)=(OD 450 value of each group/OD 450 value of control group)×100%. Since the experiment was performed in three replicates, the results of the three replicate experiments were averaged and shown in FIG. 6 .
如圖6所示,由控制組、對照組的結果可知,在經過UVA光照射後,細胞中的黑色素表現量將明顯增加,顯示UVA光照射確實會促使黑色素瘤細胞產生黑色素,而這將使得肌膚產生斑點、或使肌膚整體較為暗沈,具體而言,經UVA照光後之黑色素與控制組相比增加12.06%.。而另一方面,根據對照組以及實驗組的結果可知,當細胞經過鳳梨釋迦萃取物處理後,其在UVA光下的黑色素表現量低於未經過鳳梨釋迦萃取物處理的對照組(降低約10.08%),顯示鳳梨釋迦萃取物可有效減少黑色素細胞因UVA所生成之黑色素。As shown in Figure 6, it can be seen from the results of the control group and the control group that after UVA light irradiation, the expression of melanin in cells will increase significantly, indicating that UVA light irradiation can indeed promote melanoma cells to produce melanin, which will make melanoma cells produce melanin. The skin has spots, or the skin is dull as a whole. Specifically, the melanin after UVA irradiation increased by 12.06% compared with the control group. On the other hand, according to the results of the control group and the experimental group, when the cells were treated with pineapple chardonnay extract, their melanin expression under UVA light was lower than that of the control group without pineapple chardonnay extract treatment (reduced by about 10.08 %), showing that Pineapple Shakya extract can effectively reduce the melanin produced by melanocytes due to UVA.
[ 例 7] 細胞實驗 - 鳳梨釋迦萃取物提升彈力蛋白增生 [ Example 7 ] Cell Experiment - Pineapple Sakyamuni Extract Enhances Elastin Proliferation
於此,以ELISA讀盤機(enzyme-linked immunosorbent assay reader)測定黑色素瘤細胞株B16F10經鳳梨釋迦萃取物處理後,其黑色素含量的變化。Here, the changes of the melanin content of the melanoma cell line B16F10 after being treated with the extract of pineapple chardonnay were measured by an enzyme-linked immunosorbent assay reader.
材料與儀器
1. 細胞株:人類皮膚纖維母細胞(Human skin fibroblast)CCD-966sk(生物資源保存及研究中心(BCRC),No. 60153)。
2. 培養基:將Eagle’s最低限度基本培養基(minimum essential medium,MEM,購自Gibco,15188-319)添加額外成分使其含有10 vol% FBS(fetal bovine Serum,購自Gibco,10437-028)、90 vol% 1mM 丙酮酸鈉(sodium pyruvate,購自Gibco,11360-070)、1.5g/L 碳酸氫鈉(購自Sigma)、0.1mM 非必需胺基酸(non-essential amino acid solution,購自Gibco,11140-050)。
3. 磷酸緩衝鹽溶液(PBS溶液):購自Gibco,產品編號10437-028。
4. ELISA reader(BioTek,FLx 800)。
5. Fastin™ 彈力蛋白檢測試劑盒(Fastin™ Elastin Assay kit (Biocolor))。
6. 鳳梨釋迦萃取物:此實驗所使用的鳳梨釋迦萃取物係以例1之方式製備而成。Materials and
實驗步驟Experimental procedure
實驗將會分為實驗組以及對照組(未添加鳳梨釋迦萃取物之組別)二組進行,各組分別進行三重複試驗: 1. 將CCD-966sk細胞以每孔1×105 個的方式,接種於每孔含2ml培養基之6孔培養盤中。 2. 將培養盤置於5%CO2 、37℃環境下,培養24小時。 3. 而後,在不干擾附著細胞的情況下,移除每孔之培養基。 4. 控制組及實驗組均加入2mL的新鮮DMEM培養液。其中,實驗組之培養液額外加入以例1之方式所製備之鳳梨釋迦萃取物,使其濃度為0.5mg/mL。 5. 反應後,將細胞於37℃下培養48小時。 6. 而後,移除培養基,並以PBS溶液清洗細胞1次。 7. 將200μl胰蛋白酶(Trypsin-EDTA (10X),購自Gibco;產品編號15400-054)加至每孔中反應3分鐘。反應後,添加6 mL培養基溶液終止反應。而後收集各孔中之懸浮細胞與培養基至對應的1.5 ml離心試管內,將各離心試管以300 xg離心5分鐘使細胞沉澱。 8. 以PBS溶液清洗沉澱細胞二次後,再以200μL PBS溶液重新懸浮細胞。 9. 再次將各離心試管以300 xg離心5分鐘使細胞沉澱,再以約300μL PBS溶液重新懸浮細胞。 10. 接著,於前述細胞懸浮液中加入100 μL 1.0M的草酸(oxalic acid)後,將其於100℃中培養1小時。 11. 於每個試管中加入等體積的彈性蛋白沉澱試劑。蓋上離心管並短暫渦旋混合。靜置15分鐘以完成沉澱並將其以10,000 xg離心10分鐘。 12. 去除離心管內的液體後,添加1毫升染料試劑。將試管放在機械振盪器上,孵育90分鐘。 13. 去除剩餘染劑。而在管的底部和內部下壁中的紅棕色沉積物正是彈性蛋白-染料複合物。 14. 向每個試管中加入250μl染料解離試劑。蓋上管子,借助渦旋混合器將染料釋放到溶液中。確保所有結合的染料都已進入溶液。 15. 將每個試管的內容物轉移到96孔板中,然後將板放入ELISA讀數器中。在513nm處測量吸光度。 16. 通過Microsoft Excel中的Student t檢驗確定兩個樣本總體之間差異的統計顯著性。 (*:p <0.05; **:p <0.01; ***:p <0.001)。 17. 將100μL待檢測樣本移入一96孔盤,使用ELISA讀盤機測量細胞溶液在513nm的光密度值(optical density,OD450 ),作為吸光度。The experiment will be divided into two groups: the experimental group and the control group (the group without the addition of pineapple succulent extract), and each group will carry out three repeated experiments: 1. The CCD-966sk cells are 1×10 5 cells per well. , inoculated in a 6-well culture dish containing 2 ml of medium per well. 2. Incubate the plate in 5% CO 2 at 37°C for 24 hours. 3. Then, without disturbing the attached cells, remove the medium from each well. 4. Both the control group and the experimental group were added with 2 mL of fresh DMEM medium. Among them, the culture medium of the experimental group was additionally added with the pineapple sacha extract prepared in the manner of Example 1, so that the concentration was 0.5 mg/mL. 5. After the reaction, the cells were incubated at 37°C for 48 hours. 6. Then, remove the medium and wash the cells once with PBS solution. 7. Add 200 μl trypsin (Trypsin-EDTA (10X), available from Gibco; Product No. 15400-054) to each well for 3 minutes. After the reaction, 6 mL of medium solution was added to stop the reaction. Then, the suspended cells and medium in each well were collected into corresponding 1.5 ml centrifuge tubes, and each centrifuge tube was centrifuged at 300 x g for 5 minutes to pellet the cells. 8. After washing the pelleted cells twice with PBS, resuspend the cells with 200 μL of PBS. 9. Pellet the cells by centrifuging each tube again at 300 x g for 5 minutes and resuspend the cells in approximately 300 μL of PBS solution. 10. Next, 100 μL of 1.0 M oxalic acid was added to the cell suspension, followed by incubation at 100° C. for 1 hour. 11. Add an equal volume of Elastin Precipitation Reagent to each tube. Cap the centrifuge tube and vortex briefly to mix. Let stand for 15 minutes to complete the pellet and centrifuge at 10,000 xg for 10 minutes. 12. After removing the liquid from the centrifuge tube, add 1 mL of dye reagent. Place the tube on a mechanical shaker and incubate for 90 minutes. 13. Remove remaining stain. The reddish-brown deposits in the bottom and inner lower wall of the tube are the elastin-dye complexes. 14. Add 250 μl of dye dissociation reagent to each tube. Cap the tube and release the dye into the solution with the help of a vortex mixer. Make sure that all bound dye has gone into solution. 15. Transfer the contents of each tube to a 96-well plate and place the plate in an ELISA reader. Absorbance was measured at 513 nm. 16. Statistical significance of differences between two sample populations was determined by Student's t-test in Microsoft Excel. (*: p <0.05; **: p <0.01; ***: p < 0.001). 17. Transfer 100 μL of the sample to be tested into a 96-well plate, and use an ELISA plate reader to measure the optical density (OD 450 ) of the cell solution at 513 nm as the absorbance.
實驗結果Experimental results
實驗組以及控制組的黑色素相對表現量係依下列公式計算:黑色素相對表現量(%)=(各組OD450 值/控制組OD450 值)×100%。因實驗係進行三重複,故將三重複實驗之結果平均後,顯示於圖7。The relative expression of melanin in the experimental group and the control group was calculated according to the following formula: relative expression of melanin (%)=(OD 450 value of each group/OD 450 value of control group)×100%. Since the experiment was performed in triplicate, the results of the triplicate experiments were averaged and shown in FIG. 7 .
如圖7所示,由控制組以及實驗組的結果可知,當細胞經過鳳梨釋迦萃取物處理後,其彈力蛋白分泌量有所提升(較控制組高約4.79%),顯示鳳梨釋迦萃取物可有效提升彈力蛋白分泌量。而彈力蛋白是細胞外基質的關鍵蛋白,其具有很大的彈性,一重要功能便是使體內許多組織在拉伸或收縮後恢復其形狀。除此之外,彈性蛋白還是體內重要的承重組織,亦可用於儲存機械能。同時,彈性蛋白亦能使肌膚保持彈性,隨著年齡老化而喪失肌膚彈性的原因之一便是彈性蛋白的流失。因此,本發明之鳳梨釋迦萃取物可用於製備提升肌膚彈力、減緩肌膚老化、或提升肌膚儲存機械能之能力之組合物。As shown in Figure 7, from the results of the control group and the experimental group, when the cells were treated with pineapple sakya extract, their elastin secretion was increased (about 4.79% higher than that of the control group), indicating that the pineapple sakya extract can increase the secretion of elastin. Effectively increase the secretion of elastin. Elastin is a key protein in the extracellular matrix. It has great elasticity and an important function is to allow many tissues in the body to restore their shape after stretching or contraction. In addition, elastin is an important load-bearing tissue in the body and can also be used to store mechanical energy. At the same time, elastin can also keep the skin elastic. One of the reasons for the loss of skin elasticity with age is the loss of elastin. Therefore, the pineapple charcoal extract of the present invention can be used to prepare a composition for improving skin elasticity, slowing skin aging, or improving the ability of skin to store mechanical energy.
[ 例 8] 基因實驗 - 粒線體活性相關基因 [ Example 8 ] Gene experiment - mitochondrial activity-related genes
此範例以RNA萃取套組、反轉錄酶、KAPA SYBR® FAST qPCR試劑組配合定量PCR儀,測定人類皮膚纖維母細胞(Human skin fibroblast)CCD-966sk經本發明之鳳梨釋迦萃取物處理後,細胞中粒線體活性相關基因的變化。In this example, RNA extraction kit, reverse transcriptase, KAPA SYBR® FAST qPCR reagent kit and quantitative PCR instrument are used to determine the amount of human skin fibroblast CCD-966sk treated with the pineapple chardonnay extract of the present invention. Changes in genes associated with mitochondrial activity.
材料與儀器
1. 細胞株:人類皮膚纖維母細胞(Human skin fibroblast)CCD-966sk(生物資源保存及研究中心(BCRC),No. 60153)。
2. 培養基:將Eagle’s最低限度基本培養基(minimum essential medium,MEM,購自Gibco,15188-319)添加額外成分使其含有10 vol% FBS(fetal bovine Serum,購自Gibco,10437-028)、90 vol% 1mM 丙酮酸鈉(sodium pyruvate,購自Gibco,11360-070)、1.5g/L碳酸氫鈉(購自Sigma)、0.1mM非必需胺基酸(non-essential amino acid solution,購自Gibco,11140-050)。
3. 磷酸緩衝鹽溶液(PBS溶液):購自Gibco,產品編號10437-028。
4. RNA萃取試劑套組(購自Geneaid公司,台灣,Lot No. FC24015-G)。
5. 反轉錄酶(SuperScript® III Reverse Transcriptase) (Invitrogen公司,美國,編號18080-051)。
6. 測量標的基因引子,其中包含HAS2基因、HAS3基因、KRT1基因、KRT14基因、AQP3基因、GBA基因及FLG基因,另包括內部控制組(TBP基因)。
7. KAPA SYBR® FAST qPCR試劑組(購自Sigma公司,美國,編號38220000000)。
8. ABI StepOnePlusTM即時PCR系統(ABI StepOnePlusTM Real-Time PCR system(Thermo Fisher Scientific公司,美國))。
9. 鳳梨釋迦萃取物:由本案例1所述之製備方式所得之鳳梨釋迦萃取物。Materials and
實驗步驟 細胞培養的實驗流程如下: 1. 首先以每孔1×105 個細胞量培養於含有2 mL上述培養液之六孔培養盤中,並在37℃下培養16小時,然後將CCD-966sk細胞分為實驗組與控制組。 2. 實驗組:每毫升培養液含有0.25 mg範例一之方式製備而成之鳳梨釋迦萃取物的比例(即,濃度為0.25 mg/mL)製得含萃取物的培養液,將CCD-966sk細胞更換為含萃取物的培養液中繼續培養。 3. 控制組:不做任何處理,即不額外添加其他化合物至含有培養後的CCD-966sk細胞的培養液中。 4. 實驗組與控制組於培養6小時後,將培養後的實驗組與控制組細胞以RNA萃取試劑套組的細胞裂解液分別破細胞膜以形成二組的細胞溶液。 聚合酶連鎖反應的實驗流程如下: 1. 使用RNA萃取試劑套組分別收集二組細胞溶液內之RNA。 2. 接著,每組取2000奈克(ng)所萃取出的RNA為模板,藉由SuperScript® III反轉錄酶以表2中之引子(primer)黏合進行反轉錄作用產生相應之cDNA。 3. 後續利用ABI StepOnePlusTM Real-Time PCR system,以及KAPA SYBR FAST將二組反轉錄後產物分別以表2之組合引子進行定量即時反轉錄聚合酶連鎖反應(quantitative real-time reverse transcription polymerase chain reaction),以觀察實驗組和控制組的CCD-966sk細胞的基因的表現量。定量即時反轉錄聚合酶連鎖反應的儀器設定條件為95 °C反應1秒,60 °C反應20秒,總共40個迴圈。 4. 爾後,使用2-ΔΔCt 方法測定目標基因的相對表現量。所謂相對表現量定義為實驗組之一目標基因相對於控制組或對照組之同一基因的RNA表現量倍數變化。該方法以GAPDH基因的循環閾值作為內部對照之參考基因的循環閾值(Ct),按照以下公式計算倍數變化: △Ct = Ct實驗組之目標基因 / 控制組或對照組之目標基因 - Ct GAPDH △△Ct= △Ct實驗組之目標基因 - △Ct控制組之目標基因 倍數變化 = 2-ΔΔCt 平均值 5. 最終,利用Excel軟體之STDEV公式計算標準差,並在Excel軟體中以單尾Student t-test分析是否具有統計上顯著差異 (*p值<0.05; **p值<0.01; ***p值<0.001)。其中,PARP1基因對應的引子對為PARP1-F以及PARP1-R,PARP2基因對應的引子對為PARP2-F以及PARP2-R,NADSYN基因對應的引子對為NADSYN-F以及NADSYN-R,GAPDH基因對應的引子對為GAPDH-F以及GAPDH-R。相關引子之名稱、序列編號、序列、基因長度及基因ID可參見以下表2。Experimental Procedures The experimental procedure of cell culture is as follows: 1. First, 1×10 5 cells per well were cultured in a six-well culture dish containing 2 mL of the above-mentioned culture medium, and incubated at 37°C for 16 hours, and then the CCD- 966sk cells were divided into experimental group and control group. 2. Experimental group: The ratio of 0.25 mg of the pineapple sorghum extract prepared in the method of Example 1 per ml of culture solution (ie, the concentration is 0.25 mg/mL) to prepare the culture solution containing the extract, and the CCD-966sk cells Continue culturing in medium containing extract. 3. Control group: no treatment, that is, no additional compounds were added to the culture medium containing the cultured CCD-966sk cells. 4. After culturing for 6 hours in the experimental group and the control group, the cells of the experimental group and the control group were cultured with the cell lysate of the RNA extraction reagent kit to break the cell membrane respectively to form the cell solution of the two groups. The experimental procedure of the polymerase chain reaction is as follows: 1. Use the RNA extraction reagent kit to collect RNA from two groups of cell solutions. 2. Next, take 2000 nanograms (ng) of the extracted RNA for each group as a template, and use SuperScript® III reverse transcriptase to reverse transcription with the primers in Table 2 to generate the corresponding cDNA. 3. Subsequent use of ABI StepOnePlusTM Real-Time PCR system and KAPA SYBR FAST to carry out quantitative real-time reverse transcription polymerase chain reaction (quantitative real-time reverse transcription polymerase chain reaction). , to observe the expression level of genes in CCD-966sk cells in the experimental group and the control group. The instrument settings for quantitative real-time reverse transcription polymerase chain reaction were 95 °C for 1 sec and 60 °C for 20 sec, for a total of 40 cycles. 4. Then, use the 2- ΔΔCt method to determine the relative expression of the target gene. The so-called relative expression is defined as the fold change of the RNA expression of a target gene in the experimental group relative to the control group or the same gene in the control group. In this method, the cycle threshold of GAPDH gene is used as the cycle threshold (Ct) of the reference gene for internal control, and the fold change is calculated according to the following formula: △Ct = target gene in Ct experimental group / target gene in control group or control group - Ct GAPDH △ △Ct= △Ct experimental group target gene - △Ct control group target gene fold change = 2 - ΔΔCt average value 5. Finally, use the STDEV formula of Excel software to calculate the standard deviation, and use the one-tailed Student t in Excel software to calculate the standard deviation -test to analyze whether there is a statistically significant difference (*p-value<0.05;**p-value<0.01;***p-value<0.001). Among them, the primer pairs corresponding to PARP1 gene are PARP1-F and PARP1-R, the primer pairs corresponding to PARP2 gene are PARP2-F and PARP2-R, the primer pairs corresponding to NADSYN gene are NADSYN-F and NADSYN-R, and the corresponding primer pairs of GAPDH gene The primer pairs are GAPDH-F and GAPDH-R. The names, sequence numbers, sequences, gene lengths and gene IDs of relevant primers can be found in Table 2 below.
表2
實驗結果Experimental results
參照圖8。圖8為經本發明鳳梨釋迦萃取物處理之實驗組與未經本發明鳳梨釋迦萃取物處理之控制組的PARP1基因、PARP2基因以及NADSYN基因之相對表現量之長條圖(圖式中「*」代表p值小於0.05,「**」代表p值小於0.01,以及「***」代表p值小於0.001。當「*」越多時,代表統計上的差異越顯著)。See Figure 8. Figure 8 is a bar graph of the relative expression levels of PARP1 gene, PARP2 gene and NADSYN gene in the experimental group treated with the pineapple charcoal extract of the present invention and the control group not treated with the pineapple chardonnay extract of the present invention ("*" in the figure represents The p-value is less than 0.05, "**" means the p-value is less than 0.01, and "***" means the p-value is less than 0.001. The more "*", the more statistically significant the difference).
由該圖可知,當控制組之PARP1基因、PARP2基因以及NADSYN基因的表現量為100%時,實驗組之PARP1基因、PARP2基因以及NADSYN基因的表現量分別約為74%、68%及113%。換言之,與控制組相較之下,實驗組的人類皮膚纖維母細胞中的之之PARP1基因、PARP2基因以及NADSYN基因表現量分別降低26%、降低32%與提升13%,且均達統計學上之顯著差異。As can be seen from the figure, when the expression levels of PARP1 gene, PARP2 gene and NADSYN gene in the control group are 100%, the expression levels of PARP1 gene, PARP2 gene and NADSYN gene in the experimental group are about 74%, 68% and 113%, respectively. . In other words, compared with the control group, the expression levels of PARP1 gene, PARP2 gene and NADSYN gene in human skin fibroblasts in the experimental group were decreased by 26%, 32% and increased by 13%, respectively, and all reached statistical significance. Significant difference above.
如前所述,PARP1基因與PARP2基因各自所轉錄之蛋白質PARP1與PARP2具有抑制細胞能量分子提供者NAD+的功能。因此當PARP1與PARP2的表現量受到抑制,粒線體可保持較佳活性。而NADSYN則為NAD合成路徑重要的催化因子,其主要作用是將NaAD催化為NAD。當NADSYN表現量提升時,粒線體之活性亦將隨之提升。遂此,本發明之鳳梨釋迦萃取物具有提升粒線體活性、提升個體體力、減緩肌膚老化等功能。As mentioned above, the proteins PARP1 and PARP2 transcribed by the PARP1 gene and the PARP2 gene each have the function of inhibiting the cellular energy molecule provider NAD+. Therefore, when the expression levels of PARP1 and PARP2 are inhibited, mitochondria can maintain better activity. NADSYN is an important catalytic factor in the NAD synthesis pathway, and its main role is to catalyze NaAD to NAD. When the expression of NADSYN increases, the activity of mitochondria will also increase. Therefore, the pineapple sacha extract of the present invention has the functions of enhancing mitochondrial activity, enhancing individual physical strength, slowing down skin aging, and the like.
無none
圖式中「*」代表p值小於0.05,「**」代表p值小於0.01,以及「***」代表p值小於0.001。當「*」越多時,代表統計上的差異越顯著。 圖1是一實施例的鳳梨釋迦萃取物製備方法流程圖。 圖2是另一實施例的鳳梨釋迦萃取物製備方法流程圖。 圖3是範例三中實驗組、對照組及控制組的酪胺酸酶抑制性比例圖。 圖4是範例四中實驗組、對照組及控制組的黑色素生成比例圖。 圖5是範例五中實驗組、對照組及控制組的細胞在經紫外線照射後存活率比例圖。 圖6是範例六中實驗組、對照組及控制組的細胞在經紫外線照射後之黑色素生成比例圖。 圖7是範例七中實驗組及控制組的細胞的彈力蛋白分泌量比較圖。 圖8是範例八中實驗組及控制組粒線體活性相關基因表現量比例圖。In the graph, "*" represents a p-value less than 0.05, "**" represents a p-value less than 0.01, and "***" represents a p-value less than 0.001. The more "*", the more significant the statistical difference. FIG. 1 is a flow chart of a method for preparing a pineapple sacha extract according to an embodiment. FIG. 2 is a flow chart of a method for preparing a pineapple sacha extract according to another embodiment. Figure 3 is a graph showing the proportion of tyrosinase inhibition in the experimental group, the control group and the control group in Example 3. Figure 4 is a graph showing the proportion of melanin production in the experimental group, the control group and the control group in Example 4. FIG. 5 is a graph showing the proportion of cells in the experimental group, the control group and the control group after being irradiated with ultraviolet rays in Example 5. FIG. FIG. 6 is a graph showing the proportion of melanin production in the cells of the experimental group, the control group and the control group after being irradiated with ultraviolet light in Example 6. FIG. FIG. 7 is a graph showing the comparison of the amount of elastin secreted by cells in the experimental group and the control group in Example 7. FIG. Figure 8 is a graph showing the proportion of gene expression levels related to mitochondrial activity in the experimental group and the control group in Example 8.
Claims (9)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962953619P | 2019-12-26 | 2019-12-26 | |
US62/953,619 | 2019-12-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202123924A TW202123924A (en) | 2021-07-01 |
TWI760999B true TWI760999B (en) | 2022-04-11 |
Family
ID=76508499
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109146334A TWI787696B (en) | 2019-12-26 | 2020-12-25 | Uses of a plant fermentation liquid in preparing composition for reducing lipid |
TW109146335A TWI760999B (en) | 2019-12-26 | 2020-12-25 | Use of atemoya extract for whitening skin, improving skin elasticity, and protecting skin from uv damage |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109146334A TWI787696B (en) | 2019-12-26 | 2020-12-25 | Uses of a plant fermentation liquid in preparing composition for reducing lipid |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN113041294A (en) |
TW (2) | TWI787696B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI814026B (en) * | 2021-06-30 | 2023-09-01 | 嘉藥學校財團法人嘉南藥理大學 | Use of annona squamosa l. peel extract in preparation of composition for inhibiting matrix metalloproteinase, hyaluronidase, lipoxygenase activity and nitric oxide generation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1506041A (en) * | 2002-12-12 | 2004-06-23 | 殷冬生 | Formulation and making process of genetic skin beautifying and whitening cosmetics |
JP5144362B2 (en) * | 2008-05-02 | 2013-02-13 | 日本メナード化粧品株式会社 | Topical skin preparation |
CN105012449A (en) * | 2015-08-19 | 2015-11-04 | 庄立 | Gardenia extract with antilipemic function |
CN205378557U (en) * | 2016-02-03 | 2016-07-13 | 广西壮族自治区农业科学院园艺研究所 | Electronic pineapple sakyamuni anther collection system |
CN110051572B (en) * | 2018-01-19 | 2022-03-15 | 百岳特生物科技(上海)有限公司 | Pomegranate fermentation product and use thereof |
CN110236987A (en) * | 2019-06-27 | 2019-09-17 | 大连民族大学 | A kind of tara vine cervacoria |
-
2020
- 2020-12-25 CN CN202011566542.7A patent/CN113041294A/en active Pending
- 2020-12-25 TW TW109146334A patent/TWI787696B/en active
- 2020-12-25 TW TW109146335A patent/TWI760999B/en active
- 2020-12-25 CN CN202011572639.9A patent/CN113116770B/en active Active
Non-Patent Citations (3)
Title |
---|
網路文獻韕G Gupta-Elera ET.AL.,韕The antioxidant properties of the cherimoya (Annona cherimola) fruit. 韕 韕 韕Food Research International, 韕(2011),韕 韕 44(7), 2205-2209; * |
網路文獻韕何麗 等,韕皮膚光老化治療研究進展,韕 韕 韕中國麻風皮膚病雜誌韕2020年11期韕 韕2020年11月3日 * |
網路文獻韕德國CLR韕生化有效成份:AnnonaSense CLR™-鳳梨釋迦萃取液,韕 韕 韕2010年韕8月19日韕 韕,http://www.tannmer.com.tw/product_1225878.html * |
Also Published As
Publication number | Publication date |
---|---|
TW202123956A (en) | 2021-07-01 |
CN113116770A (en) | 2021-07-16 |
TWI787696B (en) | 2022-12-21 |
CN113116770B (en) | 2023-08-29 |
TW202123924A (en) | 2021-07-01 |
CN113041294A (en) | 2021-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI693899B (en) | Fermentation product of punica granatum and uses thereof | |
KR100958496B1 (en) | Composition from natural origin ingridient for hair loss prevention and hair growth effect | |
CN114099586B (en) | Application of muskmelon eggplant fermentation juice | |
TWI702055B (en) | Pachyrhizus erosus fermented extracts and the use thereof for enhancing the gene expression of col, timp, lox, eln, has, sod, tcp1 and ung, and for reducing the skin melanin content | |
TW201836633A (en) | Uses of orchid callus extract in protecting skin | |
TWI760999B (en) | Use of atemoya extract for whitening skin, improving skin elasticity, and protecting skin from uv damage | |
JP2018521063A (en) | Bee pollen composition | |
TW202114631A (en) | Fermentation broth of carica papaya and uses thereof for beautifying skin | |
TW202118480A (en) | Use of red grape fermented liquid for manufacturing of a composition for improving skin condition | |
TWI815071B (en) | Uses of euterpe oleracea ferment for inhibiting the activity of amylase, promoting lipid metabolism and slowing the aging process | |
TWI674107B (en) | Use of imperata cylindrica fermented extract for enhancing the gene expression of keratin, filaggrin and hyaluronan synthase, promoting the proliferation of collagen and elastin, and enhancing antioxidant capacity of skin cells | |
TWI777096B (en) | Use of extract of ginkgo biloba callus tissue for improving skin redness | |
CN106344622A (en) | Stem cell promoter and application thereof | |
TWI801770B (en) | Uses of nostoc sphaeroides extract for reducing body fat and enhancing skin appearance | |
JP3236935U (en) | Particle structure of a nutritional combination that promotes collagen and elastin biosynthesis and antioxidants | |
JP2011026240A (en) | Hair growing agent containing pollen dumpling | |
WO2024209959A1 (en) | Dermal anti-aging agent | |
TWI736759B (en) | Use of peach resin extracts for promoting gene expression of timp1, col1a2, mmp, tgm1, krt1, aqp3, gba and has3 | |
JP5866619B2 (en) | Antioxidants and whitening agents | |
CN117357572A (en) | Sophora japonica extract and its use in preparing moisturizing, anti-aging or anti-inflammatory composition | |
TW202300031A (en) | Uses of plums extract in preparing composition for improving physical function | |
JP2014237693A (en) | Whitening agent and internal or external composition comprising the same | |
TW202317166A (en) | Uses of golden passion fruit ferment for improving skin condition and anti-photoaging | |
TW202010507A (en) | Use of extract of rhinacanthus communis callus tissue for inducing expression of collagen type i gene, eln gene, has3 gene, xrcc1 gene, msh gene, sod1 gene, gpx1 gene, cat gene, tgm gene and aqp gene, promoting collagen production, and anti-oxidation, method for inducing and proliferating rhinacanthus communis callus tissue, and medium for culturing rhinacanthus communis callus tissue | |
CN114146040A (en) | Composition for strengthening skin barrier and resisting aging as well as preparation method and application thereof |